July 28 (Reuters) - The Trump administration plans to end a subsidy program that helped hold premiums for Medicare ‌drug plans, the Wall Street Journal reported on Tuesday, ‌citing government officials. The program, expected to provide insurers with roughly $3.6 billion in subsidies ​this year to cushion Medicare Part D premium increases, will not be renewed beyond 2026, the report said. Medicare Part D, which provides prescription drug coverage to millions of Medicare beneficiaries through private insurance ‌plans, is a key ⁠component of the federal health program for seniors. Nearly 25 million people were enrolled in standalone Medicare Part D prescription drug ​plans in ​2026, according to data from ​health policy research group ‌KFF. The official also said the subsidies were no longer necessary, saying that other measures ‌aimed at keeping Medicare Part D ​costs in check remain in place.